Shenzhen - Delayed Quote CNY

Tellgen Corporation (300642.SZ)

Compare
12.09
-2.77
(-18.64%)
At close: 3:04:40 PM GMT+8
Loading Chart for 300642.SZ
  • Previous Close 14.86
  • Open 14.99
  • Bid 12.08 x --
  • Ask 12.09 x --
  • Day's Range 11.89 - 14.30
  • 52 Week Range 10.65 - 19.20
  • Volume 6,641,460
  • Avg. Volume 4,221,654
  • Market Cap (intraday) 1.971B
  • Beta (5Y Monthly) 0.44
  • PE Ratio (TTM) 27.48
  • EPS (TTM) 0.44
  • Earnings Date --
  • Forward Dividend & Yield 0.15 (1.01%)
  • Ex-Dividend Date May 23, 2024
  • 1y Target Est --

Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; cardiovascular and inflammation; biochemistry kits; DNA methylation testing kits; and molecular detection of COVID-19 and others. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in 2003 and is based in Shanghai, China.

www.tellgen.com

574

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300642.SZ

View More

Performance Overview: 300642.SZ

Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300642.SZ
14.38%
SSE Composite Index (000001.SS)
7.61%

1-Year Return

300642.SZ
14.40%
SSE Composite Index (000001.SS)
0.89%

3-Year Return

300642.SZ
53.12%
SSE Composite Index (000001.SS)
4.33%

5-Year Return

300642.SZ
49.32%
SSE Composite Index (000001.SS)
9.78%

Compare To: 300642.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300642.SZ

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    2.42B

  • Enterprise Value

    2.03B

  • Trailing P/E

    34.11

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.22

  • Price/Book (mrq)

    1.61

  • Enterprise Value/Revenue

    4.39

  • Enterprise Value/EBITDA

    29.21

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.32%

  • Return on Assets (ttm)

    1.63%

  • Return on Equity (ttm)

    4.25%

  • Revenue (ttm)

    462.55M

  • Net Income Avi to Common (ttm)

    70.88M

  • Diluted EPS (ttm)

    0.44

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    476.68M

  • Total Debt/Equity (mrq)

    5.42%

  • Levered Free Cash Flow (ttm)

    5.99M

Research Analysis: 300642.SZ

View More

Company Insights: 300642.SZ

Research Reports: 300642.SZ

View More

People Also Watch